Rowan T. Chlebowski on Muck Rack

Rowan T. Chlebowski

Torrance
As seen in: Color Research & Application, Wiley, Wiley Online Library, Taylor & Francis Online, JAMA (The Journal of the American Medical Association), JAMA Oncology, JAMA: Journal of the American Medical Association, The New England Journal of Medicine, The Lancet, Dove Medical Press and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rowan T.

Contact Rowan T., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Rowan Chlebowski, M.D., Ph.D.

|
By Rowan T. Chlebowski
| City of Hope
Research Professor, Department of Medical Oncology & Therapeutics Research Rowan Chlebowski, M.D., Ph.D., is one of the most influential breast cancer researchers in the world. As a clinical breast oncologist with a Ph.D. in reproductive biology, he has a credentialed clinical and research interest in breast cancer therapy and prevention, menopausal hormone therapy influences on cancer and chronic disease, and lifestyle influences on breast cancer incidence and outcome.
Open in Who Shared Issue with article?

Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women’s Health Initiative

|
By Rowan T. Chlebowski, Aaron K. Aragaki, Kathy Pan, Michael Simon
| Wiley Online Library Verified
CONFLICT OF INTEREST STATEMENT Rowan T. Chlebowski reports receiving personal fees from Novartis, AstraZeneca, Pfizer, and UpToDate during the conduct of the study. Joanne E. Mortimer has been a consultant for AstraZeneca and Novartis. Andrew M. Kaunitz has received grants from Bayer. Robert A. Wild has received grants from Boston Heart Diagnostics and Quest Medical and holds intellectual property with Partners Health Care. The other authors declare no conflicts of interest.
Open in Who Shared Issue with article?

Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positi

|
By Reina Haque, Rowan T. Chlebowski, Nina Oestreicher, Deepa Lalla
| Dove Medical Press
Introduction About 15–20% of breast cancers have amplification of the human epidermal growth factor receptor 2 (HER2) gene or HER2 protein overexpression (“HER2-positive”), which is associated with poor clinical outcomes.1 Following the demonstration that trastuzumab, a humanized monoclonal antibody that binds close to the trans-membrane domain of the HER2 protein, resulted in improved survival in HER2-positive metastatic breast cancer in combination with chemotherapy,2 clinical trials of...
Open in Who Shared Issue with article?
See all 25 licensed articles (26 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified